Category Archives: Transhuman News

LONDON, Feb. 16, 2022 /CNW/ --

(PRNewsfoto/Queen Mary University of London (QMUL),Genomics England)

study - led by Queen Mary University of London, Illumina, University College London and Genomics England, in conjunction with NHS England - highlights how whole genome sequencing robustly identifies the most common inherited neurological diseases

method now routinely utilised as a single test to support diagnosis of neurological disorders

faster diagnosis possible for conditions like Fragile X syndrome, Huntington's disease & some forms of ALS

WGS identifies neurological disorders in previously undiagnosed patients

Scientists have found whole genome sequencing (WGS) can quickly and accurately detect the most common inherited neurological disorders something previously thought to be impossible with the results supporting the use of WGS as a standard diagnostic tool within routine clinical practice.

The study published today in The Lancet Neurology was led by Queen Mary University of London, Illumina, University College London and Genomics England, in conjunction with NHS England and assessed the diagnostic accuracy of WGS against the test used as standard across the NHS.

This study evaluated the role of WGS in the commonest causes of inherited neurological diseases that usually require multiple tests, a process that results in a long diagnostic odyssey. These repeat expansion disorders have short repetitive DNA sequences that cause disorders such as Fragile X syndrome (intellectual disability), Huntington's disease, Friedreich's ataxia (FA) and some forms of amyotrophic lateral sclerosis (ALS) and frontal lobe or frontotemporal dementia (FTD).

The study first analysed the accuracy of WGS to detect repeat expansion disorders by comparing the test currently in use, PCR (polymerase chain reaction), with WGS from 404 patients previously tested in the NHS. The findings highlighted the accuracy and sensitivity of WGS in detecting these kinds of conditions was equivalent to using PCR tests.

Story continues

Then, the study used WGS from 11,631 undiagnosed people who had clinical features associated with a repeat expansion disorder who are participants in the 100,000 Genomes Project. Among the 68 people who benefited from a diagnosis were six children, some of whom did not have a reported family history of repeat expansion disorders and who previously did not receive a diagnosis, including a 10-year-old girl with an intellectual disability and an 18-year-old teenager with dementia.

The study demonstrated a quicker and more efficient diagnosis can be achieved through whole genome analysis for those patients who have not previously received a diagnosis replacing multiple tests over months or years.

This is because PCR tests are often locus-specific, meaning only one gene is looked at each time. The process is time-consuming and results in the underdiagnosis of people who have atypical clinical presentations, especially children without a previous positive family history. By contrast, a single WGS test can diagnose many disorders.

The findings support using whole genome sequencing within the NHS to diagnose patients whose doctors believe may have a repeat expansion disorder. The benefits of doing so would include:

supplying an answer for a previously undiagnosed condition

relatives knowing that the genetic condition runs in the family

improved understanding of how frequently a genetic mutation appears in the population

an increase in clinical drug / treatment trials

Professor Sir Mark Caulfield from Queen Mary University of London and former Chief Scientist at Genomics England, said: "This represents a major advance in the application of whole genomes enabling detection of previously unexpected inherited neurological disorders. At the moment, diagnosing this type of neurological disorder often depends on people having a family history of the disease or specific clinical symptoms, using WGS we can detect these and new repeat expansion disorders."

Dr Arianna Tucci, Medical Research Council Clinician Scientist fellow at Queen Mary University of London and University College London, said: "Repeat expansion disorders are estimated to affect 1/3000 people. Before this study, it was thought to be difficult to diagnose them using whole genome sequencing. Our study validates the use of whole genome sequencing, a newly introduced genetic test in the National Health Service, to diagnose the commonest form of inherited neurological diseases."

Dr Richard Scott, Chief Medical Officer at Genomics England, said: "This is a clear example of the sort of innovation that we are proud to have helped accelerate and of the impact the UK has been able to have by linking research with routine care in genomics. This work has allowed us to deploy new tools that can detect variation in the genome that more targeted sequencing misses. This has already led to diagnoses and better care for the families with rare disease in the 100,000 Genomes Project and is being used to support diagnosis in the NHS Genomic Medicine Service."

Dr Ryan Taft, Vice President of Scientific Research at Illumina, said: "This study demonstrates that whole genome sequencing can be used in clinical laboratories for the diagnosis of patients who have a neurological disorder, such as Huntington's disease. For the large percentage of patients with suspected repeat expansion disorders who remain undiagnosed, this should bring hope that a diagnosis may soon be possible."

Professor Dame Sue Hill, Chief Scientific Officer for England, said: "This research demonstrated the power of whole genome sequencing in helping to detect common neurological conditions and how it can lead to faster and more accurate diagnoses. We are already seeing the benefit of WGS in a clinical setting through the NHS Genomic Medicine Service and this research further proves the benefits of this kind of testing."

Eileen, a patient at The Ataxia Centre in London and who was diagnosed with Friedreich's ataxia through the study, said: "Having Friedreich ataxia has taken away everything I've loved. Over the last 15 years I've gone from someone who was confident, loved to dance and socialise to now using a walker and having slurred speech. Now when I meet people, I immediately think that they might be judging me.

"Before my diagnosis, I thought it would be better if I had cancer as there's usually a clear path of action to help you fight the disease. Having a diagnosis isn't a cure, but at last I knew what was happening and to understand what I needed to do to delay the inevitable for as long as possible. I do Pilates and work with a personal trainer twice week to maximise my strength and fitness to combat the progression. I am grateful to the London Specialist Ataxia Centre whose research programme allowed me to have a definitive genetic diagnosis, that otherwise would have taken many years to be made, if at all. I feel it is beneficial for patients with rare diseases to go to specialist centres where research is ongoing.

"Just as importantly, getting definitively diagnosed meant my family could also have a genetic test. Sadly, the Ataxia Centre could swiftly confirm that my younger sister also has FRDA so she's doing everything to combat progressions.

"There are currently no cures for FRDA but I'm looking to the future with much more optimism hopefully there will be a treatment in the not-so-distant future."

Professor Patrick Chinnery, Clinical Director at the Medical Research Council, said: "Many patients with neurological disorders never receive a precise diagnosis. This new study shows how whole genome sequencing can address this challenge through a genuinely national programme, taking world-leading research to patients across the whole of England and improving their health care."

NOTES TO EDITORS

This research was funded by the National Institute for Health Research, Wellcome, Medical Research Council, Cancer Research UK, Department of Health and Social Care, and NHS England.

About Genomics England (https://www.genomicsengland.co.uk)

Genomics England works with the NHS to bring forward the use of genomic healthcare and research in Britain to help people live longer, healthier lives. Genomics is a ground-breaking area of medicine that uses our unique genetic code to help diagnose, treat and prevent illnesses. Established in 2013, Genomics England launched the world-leading 100,000 Genomes Project with the NHS, demonstrating how genomic insights can help doctors across the NHS, and building a foundation for the future by assembling a unique dataset. The project was achieved thanks to patients and participants helping to shape it and guiding decisions on data and privacy.

Genomics England is now expanding its impact. Our next chapter involves working with patients, doctors and scientists to improve genomic testing in the NHS and help researchers access the health data and technology they need to make new medical discoveries and create more effective, targeted medicines for everybody.

About the 100,000 Genomes Project

The 100,000 Genomes Project is a now-completed UK Government project managed by Genomics England that sequenced whole genomes from NHS patients. The project focused on rare diseases, some common types of cancer, and infectious diseases.

Participants gave consent for their genome data to be linked to information about their medical condition and health records. The medical and genomic data is shared with researchers to improve knowledge of the causes, treatment and care of diseases.

Logo - https://mma.prnewswire.com/media/1683585/Genomics_England_Logo.jpg Logo - https://mma.prnewswire.com/media/1683583/Queen_Mary_Logo.jpg Logo - https://mma.prnewswire.com/media/1747437/illumina_Logo.jpg Logo - https://mma.prnewswire.com/media/1747438/UCL_Logo.jpg

illumina Logo

UCL Logo

(PRNewsfoto/Queen Mary University of London (QMUL),Genomics England)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/whole-genome-sequencing-robustly-detects-the-most-common-inherited-neurological-diseases-and-is-adopted-by-healthcare-301483632.html

SOURCE Genomics England

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2022/16/c6724.html

The rest is here:
Whole genome sequencing robustly detects the most common inherited neurological diseases and is adopted by healthcare - Yahoo Finance

Globalization is reaching at the highest level day by day and hence global market research has become quite imperative which helps businesses with decision making. An influentialSingle-Cell Genome Sequencing Marketresearch report considers several market aspects to offer solution for the toughest business questions. This market report provides estimations about the key factors of the industry with the precise and perfect data that is useful for the business. This market report takes into account key market dynamics, existing market scenario and future prospects of the sector. By carrying out top to bottom examination of the industry, the comprehensiveSingle-Cell Genome Sequencing Marketreport gives evaluations about the income, return on investment (ROI) and developing business strategies.

Two more major success factors of an influentialSingle-Cell Genome Sequencing Marketreport can be mentioned here which are market share analysis and key trend analysis. The research methodology employed in the report by DBMR research team is data triangulation which includes data mining, studying the impact of data variables on the market, and primary validation by industry experts. Being a proficient and a comprehensive in nature, this report focuses on primary and secondary market drivers, market share, leading segments and geographical analysis. With the nice blend of integrated approaches and latest technology, best results are achieved in the form of top notchSingle-Cell Genome Sequencing Marketresearch report.

DOWNLOAD SAMPLE REPORT:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-single-cell-genome-sequencing-market&Shiv

Market Analysis and Insights: Single-Cell Genome Sequencing Market

The rising prevalence of chronic diseases coupled with rising geriatric population which is most susceptible to such diseases are the two factors attributable to the growth of single-cell genome sequencing market. Data Bridge Market Research analyses that the single-cell genome sequencing market will project a CAGR of 14.5% for the forecast period of 2022-2029.

Significant market makers enrolled in this report are:

The major players covered in the single-cell genome sequencing market report are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories, Inc., Takara Bio Inc., BD, Agilent Technologies, Inc., 10x Genomics., Oxford Nanopore Technologies., BGI, Pacific Biosciences of California, Inc., DNA Electronics, Tecan Genomics, Inc., Novogene Co., Ltd., Zephyrus Biosciences, Inc., Johnson & Johnson Services, Inc., 1CellBio, Inc., Mission Bio., Fluxion Biosciences

BrowseFull TOC, Table and Figures:https://www.databridgemarketresearch.com/toc/?dbmr=global-single-cell-genome-sequencing-market&Shiv

The Single-Cell Genome Sequencing Market is sectioned based on item, twisted sort and end client. The development among these sections will assist you with breaking down small development portions in the enterprises, and furnish the clients with significant market outline and market experiences to assist them in settling on essential choices for distinguishing proof of center with showcasing applications.

The market report is portioned into the application by the accompanying classes:

Global Single-Cell Genome Sequencing Market, By Type (Instruments and Reagents), Technology (NGS, PCR, Q-PCR, Microarray and MDA), Workflow (Single Cell Isolation, Sample Preparation and Genomic Analysis), Disease Area (Cancer, Immunology, Prenatal Diagnosis, Neurobiology, Microbiology and Others), Application (Circulating Cells, Cell Differentiation, Genomic Variation, Subpopulation Characterization and Others), End User (Academic and Research Laboratories, Biotechnology and Biopharmaceutical Companies, Clinics and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

Features Major Key Factors in Single-Cell Genome Sequencing Market Report:

ACCESS FULL REPORT:https://www.databridgemarketresearch.com/reports/global-single-cell-genome-sequencing-market?utm_source=Shiv&utm_medium=Shiv&utm_id=Shiv

Cutthroat Rivalry:

The research report incorporates an investigation of the cutthroat scene present in the Single-Cell Genome Sequencing Market. It incorporates an appraisal of the current and impending patterns that players can put resources into. Moreover, it additionally incorporates an assessment of the monetary viewpoints of the players and clarifies the idea of the opposition.

Key inquiries responded to in the report include:

About US Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Sales ContactsUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Sales@databridgemarketresearch.com

Browse More Reports:

Enteral Feeding Devices Market 2022 Industry Size, Business Opportunities, Future Trends, Top Key Players and Forecast to 2029

Dental Periodontics Market 2022 Report Structure, Industry Competition Analysis, Trends and Growth, Forecast 2029

Switzerland Medical Aesthetic Market 2022 Latest Trend Analysis, Types, Applications, and Forecast to 2029

Medical Aesthetics Market Company Business Analysis, Industry Synopsis, Business Outlook 2022 to 2029

Population Health Management (PHM) Market 2022 Growth, Share, Trend, Segmentation and Forecast to 2029

Medical Device Reprocessing Market 2022 Analysis, Future Industry, Growth Rate, Key Players and Forecast to 2029

View original post here:
Single-Cell Genome Sequencing Market Business Development, Size, Share and Opportunities 2022 to 2029 The UB Post - The UB Post

BRISBANE, Calif., Feb. 14, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD) on Wednesday, February 23, 2022, from 12:00 1:00 p.m. EST.

In addition to a brief pre-clinical program overview of SG-5-00455, Second Genome's development candidate for the treatment of IBD, the event will include a presentation and a Q&A panel with renowned experts in the field, including:

A live webcast of the event will be available on the Events page of the Second Genome website at http://www.secondgenome.com/news/events and at this direct link, and a replay will be accessible following the program.

About SG-5-00455

SG-5-00455, the Company's development candidate for the treatment of IBD, could potentially be a first-in-class precision therapeutic that targets PAI-1/2 and directly improves tissue repair and mucosal healing in IBD patients. The development candidate was generated using a novel, naturally derived protein (SG-2-0776), that was subsequently engineered into a Lactococcus lactis (L. lactis) drug delivery system, SG-5-00455, for direct, non-systemic delivery to the gut. SG-5-00455 is currently in IND-enabling studies, and the Company expects to submit an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) in the second half of 2022.

About Second Genome

Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Arena Pharmaceuticals to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit http://www.secondgenome.com.

Investor Contact: Argot Partners 212-600-1902 [emailprotected]

Media Contact: Argot Partners 212-600-1902 [emailprotected]

SOURCE Second Genome

Link:
Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23 - PRNewswire

Feb. 16, 2022 13:00 UTC

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its SIRION Biotech business, a world leader in viral vector-based gene delivery technologies for gene and cell therapy and vaccine development, and the Centre for Genomic Regulation (CRG), an international biomedical research center of excellence located in Barcelona, Spain, have entered into an agreement to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas.

The collaboration combines SIRIONs AAV technology platform and expertise in viral vector development and production with CRGs deep knowledge of genetic regulatory mechanisms. The end goal is to develop AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes under control of cell-specific regulatory elements. This new approach aims to increase the precision, safety, and efficacy of future AAV based gene therapies for diabetes.

As we look to the future of precision medicine, we are excited to collaborate with CRG on new generation AAV vector technology, said Dr. Christian Thirion, founder and managing director of SIRION. The company offers one of the worlds most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite gene therapy research and advance drug development. Our hope is that our joint efforts will not only facilitate better gene therapy options for type 1 and type 2 diabetes but also bring the life science industry closer to creating more successful and specialized gene therapies for other diseases such as neuronal disorders.

CRG project leader Professor Jorge Ferrer, an expert in regulatory genomics and diabetes, said, In this joint project we will leverage our development platform for regulatory elements and harness our research results on gene networks from recent years. He added, Teaming with SIRION and translating our findings into real products and applications underscores the importance of having state-of-the art technologies and capabilities that can support others in their own endeavors. Ultimately, such applied science could improve the lives and wellbeing of people around the world.

Collaboration with world-class research organizations such as CRG expands SIRIONs viral vector technology licensing portfolio that the industry can leverage to develop new cell and gene therapies. For more information on Munich, Germany-based SIRION, a PerkinElmer company, please visit http://www.sirion-biotech.com.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at http://www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

About the Centre for Genomic Regulation

The CRG is a biomedical research center based in Barcelona, Spain which has launched five spin-off companies since 2008. It is home to more than 400 interdisciplinary scientists focused on understanding the complexity of life, from the genome to the cell and the entire organism, and recently created a Medical Genomics Programme. The CRG is a center with a unique research model, focused on recruiting internationally renowned group leaders. It hosts the European Genome-Phenome Archive together with EMBL-EBI, and is partnered with EMBL Barcelona. The CRG is a member of the Barcelona Institute of Science and Technology (BIST) and a CERCA centre within the research system of the Catalan Government.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," estimates, "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions, and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdoms withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220216005286/en/

See the article here:
PerkinElmer's SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene...

Genome Sequencing Marketresearch report begins with a market outlook together with the data integration and capabilities study with the appropriate findings. It has projected strong upcoming growth of the market. The document gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market, and comprising key regions. The persuasive Market research report enumerates information about the key companies based on their market position in the present scenario along with data related to the market sales gathered by the manufacturers along with the industry share. Information about the revenue gathered from the segments along with the projected sales for the project duration is stated in the document. Besides, essential insights about the fundamental parameters such as the competition trends and market focusing rate are included in the report.

The genome sequencing market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 15.73% in the forecast period of 2021 to 2028 and is estimated to reach 41,151.61 USD million by 2028. The growing of the prevalence of the cancer will help in escalating the growth of the genome sequencing market.

Download Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genome-sequencing-market&shrikesh

Genome sequencing is the procedure of mapping and sequencing of the unique DNA of a person. Genome signifies the entire blueprint of a persons human body. Genome sequencing aids to identify any important differences in the genes, which are a bundle of DNA, in a persons body which can cause a disease or upsurge the likelihood of a disease.

Segmentation:

Global Genome Sequencing MarketBy Product (Consumables, Systems & Software, Services), Technology (PCR, Sequencing, Microarray, Nucleic Acid Extraction & Purification, Others), Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Agriculture & Animal Research, Others), End-User (Research Centers, Academic & Government Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East And Africa) Industry Trends & Forecast to 2026

List of Top Key Vendors:

The major players covered in the genome sequencing market report are Thermo Fisher Scientific, Illumina, Inc., QIAGEN, Eurofins Scientific, Agilent Technologies, Inc., Oxford Nanopore Technologies., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., BGI, Danaher., General Electric Company, Eppendorf AG, Abbott, LI-COR, Inc., Siemens, PerkinElmer Inc., Macrogen Inc., DNASTAR, Geneious, Myriad Genetics, Inc., GATC Biotech, Biomatters, New England Biolabs, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-genome-sequencing-market&shrikesh

The genome sequencing market is segmented on the basis of product, technology, application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

The genome sequencing market is analysed and market size insights and trends are provided by country, product, technology, application and end user as referenced above.

The countries covered in the genome sequencing market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genome sequencing market because of the nonstop technological advancements by the key players. Furthermore, the high investment in research and development, and the accessibility of scientifically developed of healthcare infrastructure which will boost the growth of the genome sequencing market in the region during the forecast period. Asia Pacific is projected to observe significant amount of growth in the genome sequencing market because of the calculated initiatives undertaken by the international firms to extend their occurrence because of the high customer base.

Provided for Major Regions as Follows:

Some Point of Table of Content:

Table of Content:

Chapter 1: Market Overview

Chapter 1.1: Study Assumptions

Chapter 1.2: Scope of the Study

Chapter 2: Market Economic Impact

Chapter 2.1: Analysis Methodology

Chapter 2.2: Research Phases

Chapter 3: Competition by Manufacturers

Chapter 3.1: Current Market Scenario

Chapter 3.2: Value Chain/Supply Chain Analysis

Chapter 3.3: Government Regulations and Initiatives

Chapter 4: Production, Revenue (Value) by Region

Chapter 5: Supply (Production), Consumption, Export, Import by Regions

Chapter 5.1: Market Drivers

Chapter 5.2: Market Restraints/Challenges

Chapter 5.3: Market Opportunities

Chapter 6: Production, Revenue (Value), Price Trend by Type

Chapter 7: Market Analysis by Application

Chapter 8: Market by Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Geographic Analyses

Chapter 12: Market Effect Factors Analysis

Highlights of this Study Market Research Report:1. To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders2. To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)3. Key parameters which are driving this market and restraining its growth4. What all challenges manufacturers will face as well as new opportunities and threats faced by them.5. Learn about the market strategies that are being adopted by your competitors and leading organizations

Some of the key questions answered in this report: Detailed Overview of this Market helps deliver clients and businesses making strategies. Influential factors that are thriving demand and constraints in the market. What is the market concentration? Is it fragmented or highly concentrated? What trends, challenges and barriers will impact the development and sizing of this Market? SWOT Analysis of each key players mentioned along with its company profile with the help of Porters five forces tool mechanism to compliment the same. What growth momentum or acceleration market carries during the forecast period?

Top DBMR Healthcare Reports:

https://www.marketwatch.com/press-release/cyclophilin-inhibitors-therapeutics-market-share-application-analysis-regional-outlook-competitive-strategies-forecast-up-to-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/fitness-app-market-share-worldwide-industry-growth-size-statistics-opportunities-forecasts-up-to-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/dental-imaging-x-ray-market-size-share-and-forecast-2021-2028-north-america-expected-to-have-the-major-market-share-globally-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/nursing-education-market-size-share-and-forecast-2028-segmentation-key-insights-and-company-profiles-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/insufflation-needles-market-size-share-industry-growth-analysis-segmentation-overview-and-forecast-till-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/nephropathic-cystinosis-treatment-market-2021-outlook-growth-by-top-companies-regions-types-applications-drivers-trends-forecasts-by-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/facial-fat-transfer-market-trends-analysis-top-manufacturers-shares-growth-opportunities-statistics-forecast-to-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/pain-management-therapeutics-market-outlook-strategies-manufacturers-countries-type-and-application-global-forecast-to-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/respiratory-inhalers-market-2021-outlook-growth-by-top-companies-regions-types-applications-drivers-trends-forecasts-by-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/north-america-excipients-market-global-industry-analysis-competitive-insight-and-key-drivers-research-report-2021-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/middle-east-and-africa-neuroendocrine-tumors-market-global-market-estimation-dynamics-regional-share-trends-competitor-analysis-to-2028-2022-02-14?mod=search_headline

https://www.marketwatch.com/press-release/drug-addiction-treatement-market-forecast-2021-2028-by-regions-type-and-application-with-sales-and-revenue-analysis-2022-02-14?mod=search_headline

View post:
Genome Sequencing Market 2021- Global Industry Analysis, By Key Players, Segmentation, Application, Demand And Forecast By 2028 The UB Post - The UB...

Food security is a global priority and it is becoming more urgent in the face of climate change, which is already affecting crop productivity. One way to improve food security is to increase crop yields.

But this is not easy. Research has shown that in the past two decades plant breeders have been unable to increase yields of staple crops at the rate at which the worlds population is growing.

New technologies are needed to achieve this rate. Over the past decade several novel technologies have been developed. These are known as New Breeding Techniques and have the potential to hugely help in growing efforts.

Genome editing is one such technique. It allows the precise editing of genomes that is, the genetic information an organism contains. Scientists worldwide have embraced the technology. And countries that adopted New Breeding Techniques early have seen a significant increase in the development of locally relevant products. Current crops under development include ones resistant to specific diseases and insect pests, that are healthier to eat or which are tolerant of drought or heat stress.

Both small, micro and medium enterprises and the public sector in these countries have been involved in developing and using genome edited crops. This should translate to improved economic growth and employment opportunities.

Read more: What is CRISPR, the gene editing technology that won the Chemistry Nobel prize?

Whatever approach a country chooses, it must be underpinned by regulation. This ensures a framework for the introduction of new products that benefit consumers and stimulate the bio-economy in a sustainable manner.

South Africas authorities have taken what we think is an unfortunate approach to regulating genome-edited plants. In October 2021 the government classified genome-edited plants as genetically modified crops. This is based on its interpretation of the definition of a genetically modified organism in a 25-year-old piece of legislation rather than on recent science-based risk analysis considerations.

As experts in plant biotechnology we fear that this regulatory approach will greatly inhibit the development of improved crops for South African farmers. It will place an unnecessary regulatory burden on bio-innovators. This will discourage local investment for in-house research and development, as well as projects in the public sector. Local entrepreneurs who aim to enhance local crops climate resilience or to develop speciality products for niche markets through genome editing will be thwarted by the need to raise disproportionate funding to fulfil current regulations.

Crop plants are improved by generating genetic variation that leads to beneficial traits. Plant breeders traditionally achieved this by crossing different varieties of the same plant species. These approaches alter many genes; the result is that traditionally-bred plants contain both advantageous and deleterious traits. Removing disadvantageous traits before the crop can be commercialised is a costly, time-consuming process.

In the 1980s, transgenic genetic modification technologies were developed. These rely on pieces of DNA from one species being integrated into the genome of a crop. Such genetically modified (GM) plants are highly regulated internationally. In South Africa the legislation governing these plants came into force in 1999. The use of GM technology in South Africa and other countries has been highly successful.

For example, it has led to South Africa doubling maize productivity, making it a net exporter of this commodity. This contributes to food security and also generates foreign income, which reduces the countrys trade deficit.

But the regulations governing GM plants are onerous: only large agricultural biotechnology companies have the resources to commercialise them. This is done to the eliminate risk that GM plants containing new DNA are harmful for health or to the environment.

Because of this, all GM plants licensed for commercial use in South Africa come from a small number of international companies. Not a single locally developed product has been commercialised during the past three decades, despite South Africa being an early adopter of the technology. This hampers the development of novel crops and the improvement of traditional crops, especially for emerging and subsistence farmers in sub-Saharan Africa.

Thats why newer tools like genome editing are so exciting. They can be used to introduce genetic variation for crop improvement in a fraction of the time it would take using conventional methods. Some forms of genome editing are transgenic in nature, while others arent because they dont involve the insertion of foreign DNA into a plant.

This approach mimics the effect of traditional plant breeding, but in a highly targeted manner so that only advantageous traits are introduced. For example, genome editing is being used to produce peanuts, soybean and wheat that do not produce allergens.

Its working well. Despite the technology only being available for a decade, some crops produced using genome editing are already on the market in some countries, including soybean and tomatoes which are healthier for human consumption.

Regulatory authorities around the world have taken either a process- or a product-based approach to regulating GM crop safety. A process-based approach examines how the crop was produced; a product-based approach examines the risks and benefits of the GM crop on a case-by-case basis.

We believe that a product-based approach makes most sense. This is because a process-based approach could lead to the strange situation where two identical plants are governed by very different regulations, just because they were produced by different methods. The added regulatory burden imposed by this approach will also hamper innovation in developing new crops.

Our approach would mean that any plant with extra DNA inserted into the genome would be governed as a GM plant. Plants with no extra DNA added and that are indistinguishable from conventionally bred organisms should be regulated like a conventionally produced crop.

This is the most rational way to regulate these different types of organisms, as it adheres to the principles of science-based risk analysis and good governance.

Many countries, among them Argentina, China, Japan, the US, Australia, Brazil and Nigeria, have taken this approach.

Science-based risk analysis should return to the heart of regulation: concrete risk thresholds should define regulatory triggers.

Original post:
South Africa should rethink regulations on genetically modified plants - The Conversation CA

As part of the fight against Covid-19, India stated earlier this week that it is ready to expand its SARS-CoV-2 Genomics Consortium (INSACOG) network of facilities for genomic sequencing and surveillance in the neighbouring countries.

INSACOG is a consortium of 38 laboratories, initiated by the Union Health Ministry, the Department of Biotechnology (DBT), the Council for Scientific and Industrial Research (CSIR) and the Indian Council of Medical Research (ICMR), to monitor genomic variations in the SARS-CoV-2 virus.

Foreign Secretary Harsh Vardhan Shringla made this offer during his presentation at the Covid-19 Global Action Meeting, which was convened by the United States Secretary of State Antony Blinken. This meeting was also attended by foreign ministers and senior representatives from a number of countries and international organisations.

Reportedly, Shringla represented India at the conference because External Affairs Minister S Jaishankar was on an official tour abroad.

Blinken hosted the meeting to coordinate pandemic response efforts, especially in the areas of immunisation, supply chain resilience and improving global health security architecture.

However, according to reports, it is believed that as per Shringla, India will band together with like-minded nations and the World Health Organization (WHO) to enhance sub-optimal approval, as well as regulatory processes that obstruct reliable and regular supplies.

Additionally, it was said that India will endeavour to see that the TRIPS waiver that it co-sponsored with South Africa, is implemented to diversify local manufacturing in regional markets.

During the pandemic, India provided 17 training modules to more than 60 nations as part of its development assistance package.

However, according to the Foreign Secretary, India will use its experience in testing, treating and vaccinating a large population spread across various geographies and terrains to develop customised and tailored capacity building and technical training programmes for front-line and healthcare workers in Asia, Africa and Latin America.

As reported, according to some people familiar with the discussion at the meeting, Shringla stated that India has given CoWIN as an open-source digital public good and is in talks with WHO to sign a Memorandum of Understanding or MoU to share the platform globally through WHO's C-TAP (COVID Technology Access Pool) project.

Shringla noted that India has vaccinated nearly 1.7 billion people, covering 70 per cent of the adult population and the CoWIN has handled up to 25 million daily immunisations.

According to reports, Shringla said that India had provided over 162 million vaccine doses to 97 nations and two UN organisations. He reportedly also cited New Delhi's humanitarian support to Myanmar and Afghanistan.

As per those sources, India's Foreign Secretary stated that the country is working with its QUAD partners to distribute a billion doses across the Indo-Pacific region by 2022.

Shringla focused on the fact that four WHO-approved vaccines, which are Covaxin, Covishield, Covovax and Janssen (Johnson & Johnson jab), as well as three more awaiting approval for Corbevax, ZyCov-D and Gennova are being manufactured in India. According to him, India will be able to make 5 billion doses by 2022.

See the rest here:
New Push To Defeat Covid-19: India Wants To Expand Its Genomic Sequencing Capabilities To Neighbouring Countries - Swarajya